Compare iShares Gold Trust (IAU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs ResMed Inc. — how do they compare? iShares Gold Trust trades at $78.87 (market cap $61.51B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: iShares Gold Trust is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and ResMed Inc. for 51 Days on average.
| IAU | RMD | |
|---|---|---|
Market Cap | $61.51B | $31.89B |
Volume | 3,206,729 | 618,314 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $277.88 |
52-Week Low | $74.21 | $182.82 |
Typical Hold Time | 49 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $78.87, up 2.35% today, but faces strong technical bearish signals with 13 of 13 moving averages indicating sell signals. The stock shows neutral momentum oscillators with RSI levels at 40.80 (6-day) and 31.31 (12-day) suggesting potential oversold conditions. Recent market sentiment reflects gold's sensitivity to interest rate expectations and Treasury yield movements.
Investment outlook remains cautious with technical indicators predominantly bearish and gold prices facing headwinds from rising yields. The stock's proximity to key support at $76-77 creates a critical level to watch, while Federal Reserve policy decisions on interest rates will likely drive near-term direction.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
